Current Cell-Based Therapies in the Chronic Liver Diseases
Liver diseases account for one of the leading causes of deaths in global health care. Furthermore, chronic liver failure such as liver cirrhosis is, namely, responsible for these fatal conditions. However, only liver transplantation is an established treatment for this end-stage condition, although the availability of this salvage treatment option is quite limited. Thus, the novel therapy such as artificial liver devices or cellular administration has been regarded as feasible. Especially cellular therapies have been proposed in decades. The technical advancement and progress of understanding of cellular differentiation have contributed to the development of basis of cellular therapy. This attractive therapeutic option has been advanced from original embryonic stem cells to more effective cellular fractions such as Muse cells. Indeed several cellular therapies including bone marrow-derived stem cells or peripheral blood-derived stem cells were initiated; the recent most organized clinical trials could not demonstrate its efficacy. Thus, truly innovative cellular therapy is needed to meet the scientific demands, and Muse cell administration is the remaining approach to this. In this article, we will discuss the current development and status of cellular therapy toward chronic liver failure.
KeywordsLiver cirrhosis Albumin Hepatocyte Regeneration Liver failure Transaminase Bilirubin Fibrosis
This work was supported in part by the Grant-in-Aid for Scientific Research (B) (Grant #JP16H05283) from JSPS and CREST (grant #17gm0610001h0006) and Research Program on Hepatitis from AMED.
- 32.Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J et al (2018) Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol Hepatol 3(1):25–36CrossRefGoogle Scholar
- 41.Ogura F, Wakao S, Kuroda Y, Tsuchiyama K, Bagheri M, Heneidi S et al (2014) Human adipose tissue possesses a unique population of pluripotent stem cells with nontumorigenic and low telomerase activities: potential implications in regenerative medicine. Stem Cells Dev 23(7):717–728CrossRefGoogle Scholar
- 50.Life Science Institute, Inc., Press release http://www.lsii.co.jp/pdf/20180115-1.pdf (Japanese)